Keryx Biopharmaceuticals (KERX) News $KERX
Shares of KERX Up 77.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 20, 9:39AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 77.63% as of today's recent price of $15.13.
Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories
PR Newswire - Wed Mar 19, 7:41AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 688.96, up 1.17%, and the same has advanced 1.47% in the last one month. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc. (NASDAQ: IPXL). Free technical research on KERX, RIGL, SNY and IPXL can be downloaded upon signing up at:
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Keryx Biopharmaceuticals' Zerenex(TM) Data Selected for Poster Presentation at the AMCP's 26th Annual Meeting and Expo
Thomson Reuters ONE - Mon Mar 17, 7:31AM CDT
NEW YORK, March 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that data highlighting the potential pharmacoeconomic benefit of Zerenex(TM) (ferric citrate coordination complex), the Company's drug candidate for the treatment of hyperphosphatemia in dialysis patients, has been selected for poster presentation during the upcoming Academy of Managed Care Pharmacy's (AMCP) 26th Annual Meeting and Expo, being held April 1-4, 2014, at the Tampa Convention Center in Tampa, Florida.
Wider Q4 Loss at Keryx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 12:19PM CDT
Keryx Biopharmaceuticals reported a loss of 21 cents in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 19 cents per share.
79.3% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Thu Mar 13, 9:13AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 79.33% as of today's recent price of $15.27.
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"), today announced its financial results for the fourth quarter and year ended December 31, 2013.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Tue Mar 11, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for the fourth quarter and year ended December 31, 2013 and a business outlook for 2014. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.
Keryx Biopharmaceuticals submits Zerenex's MAA to EMA seeking approval for treating CKD patients
M2 - Tue Mar 11, 4:34AM CDT
Pharmaceutical company Keryx Biopharmaceuticals (NasdaqCM:KERX) disclosed on Monday the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the treatment for hyperphosphatemia in patients with chronic kidney disease (CKD), including dialysis- and non-dialysis dependent CKD.
Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
GlobeNewswire - Mon Mar 10, 9:01AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA"), seeking the approval of Zerenex(TM) (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis dependent CKD.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
93.8% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Wed Mar 05, 4:41PM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 93.78% as of today's recent price of $16.50.
Keryx Biopharmaceuticals Up 98.8% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 26, 10:57AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 98.83% as of today's recent price of $16.93.
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewswire - Wed Feb 26, 7:42AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Keryx Biopharmaceuticals Up 81.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 19, 9:36AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 81.68% as of today's recent price of $15.47.
Keryx Biopharmaceuticals Inc names Abraham Ceesay as vice president of Marketing
M2 - Wed Feb 19, 3:46AM CST
Biopharmaceutical company Keryx Biopharmaceuticals Inc (NasdaqCM:KERX) revealed on Tuesday that it has elected Abraham Ceesay as vice president of its Marketing and Operations.
3 Catalysts Biotech Investors Must Watch in 2014
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Fortunes hang in the balance. In the next few months, some investors are going to make a lot of money. Unfortunately, some will also lose a bundle. Plenty of major decisions loom large for biotech stocks in 2014. Which should investors watch most...
Shares of KERX Up 77.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 20, 9:39AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 77.63% as of today's recent price of $15.13.
Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories
PR Newswire - Wed Mar 19, 7:41AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 688.96, up 1.17%, and the same has advanced 1.47% in the last one month. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc. (NASDAQ: IPXL). Free technical research on KERX, RIGL, SNY and IPXL can be downloaded upon signing up at:
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Keryx Biopharmaceuticals' Zerenex(TM) Data Selected for Poster Presentation at the AMCP's 26th Annual Meeting and Expo
Thomson Reuters ONE - Mon Mar 17, 7:31AM CDT
NEW YORK, March 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that data highlighting the potential pharmacoeconomic benefit of Zerenex(TM) (ferric citrate coordination complex), the Company's drug candidate for the treatment of hyperphosphatemia in dialysis patients, has been selected for poster presentation during the upcoming Academy of Managed Care Pharmacy's (AMCP) 26th Annual Meeting and Expo, being held April 1-4, 2014, at the Tampa Convention Center in Tampa, Florida.
Wider Q4 Loss at Keryx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 12:19PM CDT
Keryx Biopharmaceuticals reported a loss of 21 cents in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 19 cents per share.
79.3% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Thu Mar 13, 9:13AM CDT
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 79.33% as of today's recent price of $15.27.
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease (the "Company"), today announced its financial results for the fourth quarter and year ended December 31, 2013.
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results
GlobeNewswire - Tue Mar 11, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for the fourth quarter and year ended December 31, 2013 and a business outlook for 2014. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.
Keryx Biopharmaceuticals submits Zerenex's MAA to EMA seeking approval for treating CKD patients
M2 - Tue Mar 11, 4:34AM CDT
Pharmaceutical company Keryx Biopharmaceuticals (NasdaqCM:KERX) disclosed on Monday the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the treatment for hyperphosphatemia in patients with chronic kidney disease (CKD), including dialysis- and non-dialysis dependent CKD.
Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
GlobeNewswire - Mon Mar 10, 9:01AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA"), seeking the approval of Zerenex(TM) (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis dependent CKD.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
93.8% Return Seen to Date on SmarTrend Keryx Biopharmaceuticals Call (KERX)
Comtex SmarTrend(R) - Wed Mar 05, 4:41PM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 11 months, Keryx Biopharmaceuticals has returned 93.78% as of today's recent price of $16.50.
Keryx Biopharmaceuticals Up 98.8% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 26, 10:57AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 98.83% as of today's recent price of $16.93.
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
GlobeNewswire - Wed Feb 26, 7:42AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Keryx Biopharmaceuticals Up 81.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Wed Feb 19, 9:36AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on April 23rd, 2013 at $8.52. In approximately 10 months, Keryx Biopharmaceuticals has returned 81.68% as of today's recent price of $15.47.
Keryx Biopharmaceuticals Inc names Abraham Ceesay as vice president of Marketing
M2 - Wed Feb 19, 3:46AM CST
Biopharmaceutical company Keryx Biopharmaceuticals Inc (NasdaqCM:KERX) revealed on Tuesday that it has elected Abraham Ceesay as vice president of its Marketing and Operations.
3 Catalysts Biotech Investors Must Watch in 2014
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Fortunes hang in the balance. In the next few months, some investors are going to make a lot of money. Unfortunately, some will also lose a bundle. Plenty of major decisions loom large for biotech stocks in 2014. Which should investors watch most...
